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Abstract
Objective To assess the costs and health effects of a range of
interventions for preventing the spread of HIV and for treating
people with HIV/AIDS in the context of the millennium
development goal for combating HIV/AIDS.
Design Cost effectiveness analysis based on an epidemiological
model.
Setting Analyses undertaken for two regions classified using
the WHO epidemiological grouping—Afr-E, countries in
sub-Saharan Africa with very high adult and high child
mortality, and Sear-D, countries in South East Asia with high
adult and high child mortality.
Data sources Biological and behavioural parameters from
clinical and observational studies and population based surveys.
Intervention effects and resource inputs based on published
reports, expert opinion, and the WHO-CHOICE database.
Main outcome measures Costs per disability adjusted life year
(DALY) averted in 2000 international dollars ($Int).
Results In both regions interventions focused on mass media,
education and treatment of sexually transmitted infections for
female sex workers, and treatment of sexually transmitted
infections in the general population cost < $Int150 per DALY
averted. Voluntary counselling and testing costs < $Int350 per
DALY averted in both regions, while prevention of mother to
child transmission costs < $Int50 per DALY averted in Afr-E
but around $Int850 per DALY in Sear-D. School based
education strategies and various antiretroviral treatment
strategies cost between $Int500 and $Int5000 per DALY
averted.
Conclusions Reducing HIV transmission could be done most
efficiently through mass media campaigns, interventions for sex
workers and treatment of sexually transmitted infections where
resources are most scarce. However, prevention of mother to
child transmission, voluntary counselling and testing, and
school based education would yield further health gains at
higher budget levels and would be regarded as cost effective or
highly cost effective based on standard international
benchmarks. Antiretroviral therapy is at least as cost effective in
improving population health as some of these interventions.
Introduction
The sixth millennium development goal, adopted by the United
Nations in 2000, aims to halt by 2015 and begin to reverse the
spread of HIV/AIDS. Since the millennium development goals
were set, the incidence of HIV infection and associated mortality
have continued to climb in low and middle income countries,
reaching levels of about five million new infections and three
millions deaths worldwide in 2004.1 The HIV/AIDS pandemic
now threatens the viability of health infrastructure, social
systems, and economic growth in many resource-poor
countries.2 3
Most countries face uncertain prospects of attaining the HIV
related target expressed in goal six. Shortage of resources is one
important reason for slow progress; the projected funding gap
for the year 2007 is estimated at around 50% of the need.4 In this
study we focus on two related issues—whether resources
currently available are achieving as much as they could and how
best to use any new resources that become available.
Since the adoption of the millennium development goals,
studies have examined the total costs of a comprehensive pack-
age of interventions against HIV/AIDS,5 projected the benefits
of implementing this package,6 7 and compiled cost effectiveness
estimates for different interventions.8–10 These studies provide
useful inputs into policy debates, but comparisons across
independent evaluations of particular interventions can provide
ambiguous information for policy makers, who need to know
what would occur when multiple interventions are implemented
concurrently; conversely, evaluating only a comprehensive pack-
age may not offer flexible guidance for priority setting under dif-
ferent levels of resource constraint. Therefore, a comprehensive
and standardised analysis of available interventions, singly and in
different combinations, is needed.
The millennium development goals were defined when
antiretroviral drugs were widely regarded as being prohibitively
expensive. The goal for HIV/AIDS therefore focused on reduc-
ing transmission. Since then, the annual cost of first line antiret-
rovirals has fallen from more than US$10 000 per patient to as
low as $140.11 While halting the spread of HIV infection remains
a critical—and unfulfilled—objective, there is also an urgent need
to assess the extent to which treatment improves population
health and is consistent with the intent of the goals. With the
recent price reductions, re-evaluation of the cost effectiveness of
treatment is essential.
This paper assesses the effectiveness and costs of a variety of
interventions for preventing and treating HIV/AIDS, individu-
ally and in combinations that incorporate interactions between
Further details of the methods used appear on bmj.com
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interventions in both costs and health impacts. The analyses
focus on two particular regions with high HIV/AIDS burdens,
classified using the World Health Organization epidemiological
grouping—Afr-E, which includes those countries in sub-Saharan
Africa with very high adult and high child mortality, and Sear-D,
which includes those countries in South East Asia with high
adult and high child mortality.
Methods
Another article in this series provides details on the standardised
methods used in all analyses in the series.12 In this section we
provide additional detail on methods exclusive to this paper.
Strategies for HIV/AIDS control
We considered the range of available interventions for
preventing the spread of HIV infection in generalised epidemics
and various strategies for treating people with HIV/AIDS. Our
choice of interventions (see box) was limited by available data13
and restricted to strategies that are most relevant to the epidem-
ics in sub-Saharan Africa and South East Asia, where
transmission occurs mostly through heterosexual contact. Most
interventions were evaluated at coverage levels of 50%, 80%, and
95%. For treatment of sexually transmitted infections, we consid-
ered current coverage, enhanced coverage (defined as the
current coverage level for antenatal care), and 95%. For preven-
tion of mother to child transmission and treatment with highly
active antiretroviral therapy (HAART), we used a coverage level
equal to current coverage of antenatal care—assumed to be an
achievable target in the short term.
Model
We adapted an existing model of the transmission and natural
course of HIV/AIDS that was used previously to assess the
potential impact of preventive interventions.6 The model
includes underlying regional demography, acquisition of HIV
and other sexually transmitted infections, and progression from
HIV infection to AIDS and death. Heterosexual transmission
occurs among five interacting risk groups: single men, married
men, female sex workers, single women, and married women.
The probability of transmitting HIV in a single unprotected
sexual contact between serodiscordant partners depends on the
stage of disease of the infected partner14 15 and is magnified by
the presence of other sexually transmitted infections. A descrip-
tion of the model has been published elsewhere,7 and details are
provided in the appendix on bmj.com.
We used baseline prevalence projections from the Joint
United Nations Programme on HIV/AIDS and the World
Health Organization to calibrate key parameter values for Afr-E
and Sear-D. We ran multiple simulations of the model using
parameter values sampled randomly from ranges defined by
available information (see appendix for details). Each simulation
was compared against baseline projections of prevalence by sex.
Point estimates were based on the best fitting set of parameter
values, with a wider range of parameter sets considered in uncer-
tainty analyses.
Modelling intervention effects
We evaluated interventions and their combinations incremen-
tally against a “no intervention” scenario (defined by setting con-
dom use, treatment for sexually transmitted infections, and use of
antiretroviral drugs to zero). Impacts of preventive interventions
were incorporated as changes in condom use, seeking treatment
for sexually transmitted infections, numbers of sexual partners,
probabilities of males visiting female sex workers, and ages of
sexual debut, derived from a previous synthesis of the published
literature.6 13 Prevention of mother to child transmission was
modelled directly based on HIV prevalence among women of
childbearing age and the effectiveness of nevirapine. For
HAART strategies, we assumed that treatment begins at the
onset of AIDS and that it prolongs median survival by 3-8 years,
depending on the range of available drugs and intensity of
monitoring (see appendix).
We used the estimated differences in incidence and mortality
between the “no intervention” and various intervention
strategies to calculate the number of disability adjusted life years
(DALYs) averted by each strategy.
Estimating costs
We followed the standardised approach to estimating pro-
gramme and patient costs applied in other papers in this series.12
Total costs are a combination of resource inputs and unit costs
(see table A on bmj.com). Quantities were determined by demo-
graphic and epidemiological outputs from the model, combined
with assumptions about coverage levels and uptake of the inter-
ventions.
Sensitivity and uncertainty analyses
In our sensitivity analyses we varied uncertain assumptions
about the input costs and behavioural impacts of interventions.
To allow for uncertainty around baseline behaviours and
biological assumptions, we also recomputed results using the 10
best fitting parameter sets identified during the calibration of the
model to epidemiological projections (see appendix).
Interventions for HIV/AIDS considered in this analysis
Mass media—Includes television and radio episodes and inserts in
key newspapers, repeated every two years; development and
administration costs included; effectiveness scaled by proportion
of population reporting weekly exposure to radio, television, or
newspapers
Voluntary counselling and testing—Performed in primary care
clinics for anyone requesting the services; includes training of
health workers; based on rapid test; number of tests over five year
period assumed to be twice average annual prevalence
Peer education for sex workers—Training of selected sex workers
by social workers to undertake peer education; provision of
condoms
Peer education and treatment of sexually transmitted infections for sex
workers—In addition to training of sex workers for peer education,
referrals made for testing and possible treatment of sexually
transmitted infections
School based education—Targeted at youths aged 10-18 years;
sessions provided during regular lessons to all students, to
promote prevention of HIV and other sexually transmitted
infections; includes training of selected teachers at each school
Treatment of sexually transmitted infections (general
population)—Provided in primary care facilities, available to
anyone who requests it; includes visits, drugs, counselling, advice
on protection, and condom distribution if requested;
effectiveness scaled by access and likelihood of using the services
Prevention of mother to child transmission—Information provided
to women seeking antenatal care on benefits and risks of
nevirapine for prophylaxis; pre-test counselling offered; single
dose provided to women who accept, and single dose provided to
child if delivered in a healthcare facility
Highly active antiretroviral therapy (HAART)—Standard HAART
involves monthly visits to healthcare providers, while intensive
monitoring involves weekly contact; either first line drugs only or
first line drugs plus second line drugs when required
See appendix for further details
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Results
Intervention effects
Tables 1 and 2 provide the total annual health effects for single
interventions expressed in infections and DALYs averted
compared with the “no intervention” scenario, along with the
total annual costs for each intervention in Afr-E and Sear-D. The
size of intervention benefits reported here should not be
compared with current epidemiological estimates since the “no
intervention” comparator subtracts current levels of condom use,
treatment of sexually transmitted infections, and antiretroviral
treatment. In both regions the largest number of DALYs are
averted through education and treatment of sexually transmitted
infections for sex workers, while the smallest gains are from
school based education. Tables 3 and 4 report on incremental
cost effectiveness ratios for interventions, listed in the order that
they would be added with increasing budgets if cost effectiveness
were the only consideration. The figure shows this expansion
path graphically, with the slope of the line joining any two points
indicating the incremental cost effectiveness ratio for the more
costly option (see related article by Evans et al12 for further
details).
The expansion paths for the two regions are similar. In
settings of extreme resource constraints, interventions focused
on mass media and peer education and treatment of sexually
transmitted infections for sex workers would be adopted first if
cost effectiveness were the only criterion for prioritising
interventions. In Afr-E health gains, measured in DALYs, would
be maximised by adding prevention of mother to child HIV
transmission and treatment of sexually transmitted infections in
the community next, followed by voluntary counselling and test-
ing, antiretroviral therapy, and school based education. All of
these interventions would be regarded as highly cost effective
based on standard benchmarks.12 The inclusion of second line
drugs in antiretroviral regimens would be the last addition to the
package of interventions in Afr-E. In Sear-D decision makers
considering only the maximisation of population health would
add treatment of sexually transmitted infections in the
community, voluntary counselling and testing, antiretroviral
therapy (with first line drugs), and prevention of mother to child
transmission—all meeting the benchmark for highly cost
effective interventions12—before adding school based education,
which would be categorised as “cost effective” but not “highly
cost effective,” or second line antiretrovirals, which fall just
beyond the threshold defining “cost effective” interventions.
Sensitivity and uncertainty analyses
The expansion path provides useful information on cost
effectiveness along with information on total costs and total
effects, although the use of point estimates suggests a higher
level of precision than is justified by the data. Many sources of
uncertainty cannot be captured in the usual statistical confidence
intervals, including uncertainty about the quantity of inputs
required to run a programme, the actual use of services by
patients, and unit costs. We tested the sensitivity of the rankings
to variation in the assumptions around key parameters, and the
ranking of interventions remained stable (see appendix for
details).
In Afr-E a reduction in programme costs relative to patient
costs would make treatment of sexually transmitted infections at
high coverage and school based education more cost effective. In
Sear-D an increase in programme relative to patient costs would
make preventing mother to child transmission more attractive
relative to other interventions. Uncertainty analyses also reveal
Table 1 Annual costs in international dollars ($Int),* infections averted, DALYs averted, and average cost effectiveness for various single interventions to
control HIV/AIDS in Afr-E region, compared with no intervention†
Intervention
Coverage
level
Yearly costs ($Int,
millions)
Yearly infections
averted (millions)†
Average cost effectiveness
ratio ($Int/infection averted)
Yearly DALYs averted
(millions)†
Average cost
effectiveness ratio
($Int/DALY averted)
Mass media 100% 16 0.27 58 4.5 3
Peer education for sex workers 50% 40 0.57 70 9.2 4
80% 61 0.89 68 14.3 4
95% 70 1.04 68 16.7 4
Peer education and treatment of
sexually transmitted infections for sex
workers
50% 42 0.72 58 11.6 4
80% 63 1.09 58 17.5 4
95% 74 1.26 59 20.2 4
School based education 50% 58 0.01 9448 0.1 530
80% 77 0.01 7908 0.2 444
95% 77 0.01 6704 0.2 376
Voluntary counselling and testing 95% 406 0.31 1315 5.0 82
Prevention of mother to child
transmission
ANC 161 0.19 847 4.7 34
Treatment of sexually transmitted
infections
Current 43 0.14 304 2.3 19
ANC 111 0.34 328 5.4 21
95% 229 0.45 514 7.1 32
Antiretroviral therapy:
No intensive monitoring, first line
drugs only
ANC 1350 0.05 28 038 2.4 556
Intensive monitoring, first line drugs
only
ANC 1507 0.04 34 825 2.5 596
No intensive monitoring, first and
second line drugs
ANC 6434 0.04 181 099 3.2 2010
Intensive monitoring, first and second
line drugs
ANC 6945 0.04 185 396 3.5 1977
*International dollars are a hypothetical unit of currency that has the same purchasing power that the US$ has in the United States at a given point in time. Details of this approach are
discussed elsewhere.12
†Intervention benefits are not comparable with current epidemiological estimates because results in this analysis are computed in relation to a “no intervention” comparator, which subtracts
current levels of condom use, treatment of sexually transmitted infections, and antiretroviral treatment.
ANC=antenatal care coverage level.
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stable outcomes across a range of plausible behavioural and bio-
logical assumptions in the 10 best fitting parameter sets
(calibrated to match baseline projections). In Sear-D the expan-
sion path was unchanged across the 10 parameter sets, except
that preventing mother to child transmission could enter before
the most basic antiretroviral therapy, and school based education
could move between various antiretroviral treatment strategies.
In Afr-E there was modest variation across the 10 parameter sets
in the ordering of interventions, with ambiguity in the rankings
of mass media and sex worker interventions, of preventing
mother to child transmission and treating sexually transmitted
infections in the community, and of school based education rela-
tive to voluntary counselling and testing and first line antiretro-
viral treatment.
For both regions, incremental cost effectiveness ratios all var-
ied within a range of 60% above or below the point estimate, with
the exceptions of mass media (in Sear-D), which could have a
ratio up to 70% lower; school based education, which could have
a ratio up to 2.5 times as high as the point estimate in Sear-D and
was nearly 90% lower in one parameter set for Afr-E; and treat-
ing sexually transmitted infections in the community, which
could be up to twice as costly in Afr-E as the point estimate.
Discussion
This study re-examines HIV/AIDS intervention strategies in a
way that allows critical assessment of the cost effectiveness of
current strategies and plans for the future use of extra resources
that may become available. We have evaluated interventions sin-
gly and in combination, taking into account synergies in both
costs and effects when interventions are implemented concur-
rently.
Because of the substantial uncertainties in many of our
assumptions, we suggest that our results be viewed by broad
bands of incremental cost effectiveness ratios. For example, in
sub-Saharan Africa mass media and providing education and
treatment of sexually transmitted infections for sex workers are
virtually indistinguishable in terms of incremental cost effective-
ness, but we can be more confident that school based education,
at around $Int600 per DALY averted—even subject to a relatively
wide range of uncertainty—requires greater resources to
produce a given health benefit than peer education of sex work-
ers, at less than $Int5 per DALY; or that use of second line
antiretrovirals, at around $Int5000 per DALY averted, is
substantially more costly per healthy life-year gained than the
initial introduction of first line antiretrovirals, at about $Int500
per DALY.
Implications of results
Our results indicate that syndromic management of sexually
transmitted infections can substantially reduce the health burden
of HIV/AIDS in the population. There has been extensive
debate over the role of treating sexually transmitted infections in
the prevention of HIV infection because of apparently
discrepant findings in three large, community based trials.16–20
Our results are consistent with recent syntheses of the findings
from these trials,21 22 which conclude that such treatment has
substantial potential to reduce HIV transmission, particularly in
HIV epidemics at less advanced stages, as in both of the regions
examined here (compared with the epidemic in Uganda). Our
conclusion that treating sexually transmitted infections would be
among the most cost effective interventions against HIV
transmission should, however, be revisited as new information
emerges.
Table 2 Annual costs in international dollars ($Int),* infections averted, DALYs averted, and average cost effectiveness for various single interventions to
control HIV/AIDS in Sear-D region, compared with no intervention†
Intervention
Coverage
level
Yearly costs ($Int,
millions)
Yearly infections
averted (millions)†
Average cost effectiveness
ratio ($Int/infection
averted)
Yearly DALYs averted
(millions)†
Average cost effectiveness
ratio ($Int/DALY averted)
Mass media 100% 33 0.11 309 1.8 18
Peer education for sex workers 50% 78 1.49 53 24.6 3
80% 115 2.20 52 36.1 3
95% 133 2.49 53 40.9 3
Peer education and treatment of
sexually transmitted infections for
sex workers
50% 83 1.82 45 29.9 3
80% 122 2.57 47 42.1 3
95% 141 2.85 50 46.6 3
School based education 50% 174 0.01 13 326 0.2 790
80% 175 0.02 8544 0.3 506
95% 176 0.02 7288 0.4 432
Voluntary counselling and testing 95% 207 0.32 642 5.2 40
Prevention of mother to child
transmission
ANC 268 0.04 7191 0.9 310
Treatment of sexually transmitted
infections
Current 177 0.34 522 5.6 32
ANC 297 0.66 448 10.9 27
95% 356 1.08 330 17.7 20
Antiretroviral therapy:
No intensive monitoring, first line
drugs only
ANC 550 0.03 18 884 1.0 542
Intensive monitoring, first line drugs
only
ANC 588 0.03 21 788 1.0 570
No intensive monitoring, first and
second line drugs
ANC 1671 0.03 56 718 1.3 1319
Intensive monitoring, first and
second line drugs
ANC 1774 0.03 55 188 1.4 1280
*International dollars are a hypothetical unit of currency that has the same purchasing power that the US$ has in the United States at a given point in time. Details of this approach are
discussed elsewhere.12
†Intervention benefits are not comparable with current epidemiological estimates because results in this analysis are computed in relation to a “no intervention” comparator, which subtracts
current levels of condom use, treatment of sexually transmitted infections, and antiretroviral treatment.
ANC=antenatal care coverage level.
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Another important finding is that antiretroviral therapy
would be included in a package of interventions for HIV/AIDS
in both regions on the basis of cost effectiveness. A strict literal
interpretation of the stated targets in the millennium
development goals would limit the focus to interventions that
reduce transmission, and evidence on the impact of treatment on
transmission remains limited. However, treatment offers
relatively good value for money in both regions in terms of
broad measures of population health outcomes. Cost effective-
ness ratios for first line HAART are lower than those for school
based education, and some variant of HAART falls well below
the threshold for very cost effective interventions in both
regions. Although we found the addition of second line antiret-
rovirals to be relatively costly per added year of healthy life, their
prices could well fall, as did the costs of first line treatment, which
would lower these cost effectiveness ratios accordingly.
In addition, the direct impacts of antiretroviral therapy
reported here might understate the overall social benefits of
treatment. For example, the availability of treatment may
encourage people to present voluntarily for counselling and
testing, which is critical to overcoming denial, stigma, and
discrimination—among the main barriers to effective prevention.
It would also allow key workers such as those in the medical and
education sectors to report more regularly for work, thereby
relieving staff shortages in those sectors in many countries.
These issues reinforce the finding that antiretrovirals should be
offered in combination with preventive strategies.
Limitations of study
Several limitations in this study deserve mention. Some
interventions that were not included in this analysis may be
effective strategies. In addition, the interventions that we did
include have been formulated in a small number of ways among
the many possibilities. For example, we considered a basic variant
of preventing mother to child transmission that falls short of the
most recently published official recommendations.23 Although a
regional analysis is intended to provide broad guidance to deci-
sion makers, many factors can cause variability in both costs and
effects of interventions across settings. Although they are
unlikely to affect our overall conclusions, continuing efforts are
required to expand the scope of strategies that are analysed and
consider additional alternatives for feasible implementation.
Many important uncertainties remain about the trajectory of
HIV/AIDS epidemics and the potential effectiveness of
interventions when expanded to full scale. Developing a better
understanding of sexual behaviours in different settings will be
critical, as will strengthening the empirical link between
behavioural and epidemiological models. In considering the
likely impact of interventions, we extrapolated most assumptions
from a limited number of relatively small scale studies, so precise
and reliable estimates of the effectiveness of large scale
prevention programmes are still needed.
Table 3 Annual costs in international dollars ($Int),* DALYs averted, and
incremental cost effectiveness of non-dominated† intervention combinations
to control HIV/AIDS in Afr-E region
Intervention package Yearly
costs
($Int,
millions)
Yearly DALYs
averted
(millions)‡
Incremental
cost
effectiveness
ratio
($Int/DALYs
averted)No Details
D1 Mass media 16 4.5 3
D2 D1 + peer education and treatment of
sexually transmitted infections for sex
workers, 50% coverage
57 15.6 4
D3 D1 + peer education and treatment of
sexually transmitted infections for sex
workers, 80% coverage
79 21.3 4
D4 D1 + peer education and treatment of
sexually transmitted infections for sex
workers, 95% coverage
89 23.8 4
D5 D4 + prevention of mother to child
transmission, antenatal care coverage level
249 27.3 46
D6 D5 + treatment of sexually transmitted
infections, current coverage
290 27.9 68
D7 D5 + treatment of sexually transmitted
infections, antenatal care coverage
357 28.7 80
D8 D7 + voluntary counselling and testing,
95% coverage
742 30.5 220
D9 D8 + treatment of sexually transmitted
infections, expanded to 95% coverage
859 30.9 290
D10 D9 + antiretroviral therapy, no intensive
monitoring, first line drugs only
2125 33.2 547
D11 D10 + school based education, 95%
coverage
2202 33.3 631
D12 D11 + antiretroviral therapy, intensive
monitoring, first line drugs only
2350 33.4 1144
D13 D11 + antiretroviral therapy, intensive
monitoring, first and second line drugs
7483 34.4 5175
*International dollars are a hypothetical unit of currency that has the same purchasing power
that the US$ has in the United States at a given point in time. Details of this approach are
discussed elsewhere.12
†Excludes combinations that were more costly but less effective than others (dominated
interventions) and those with higher incremental cost effectiveness ratios than more effective
options (weakly dominated interventions).
‡Intervention benefits are not comparable with current epidemiological estimates because
results in this analysis are computed in relation to a “no intervention” comparator, which
subtracts current levels of condom use, treatment of sexually transmitted infections, and
antiretroviral treatment.
Table 4 Annual costs in international dollars ($Int),* DALYs averted, and
incremental cost effectiveness of non-dominated† intervention combinations
to control HIV/AIDS in Sear-D region
Intervention package Yearly
costs
($Int,
millions)
Yearly DALYs
averted
(millions)‡
Incremental
cost
effectiveness
ratio
($Int/DALYs
averted)No Details
D1 Peer education and treatment of sexually
transmitted infections for sex workers,
50% coverage
83 29.9 3
D2 Peer education and treatment of sexually
transmitted infections for sex workers,
80% coverage
122 42.1 3
D3 Peer education and treatment of sexually
transmitted infections for sex workers,
95% coverage
141 46.6 4
D4 D3 + mass media, 100% coverage 175 47.3 51
D5 D4 + treatment of sexually transmitted
infections, 95% coverage
511 49.8 133
D6 D5 + voluntary counselling and testing,
95% coverage
693 50.4 317
D7 D6 + antiretroviral therapy, no intensive
monitoring, first line drugs only
1149 51.0 760
D8 D7 + prevention of mother to child
transmission, antenatal care coverage level
1416 51.3 850
D9 D8 + antiretroviral therapy, intensive
monitoring, first line drugs only
1443 51.3 1295
D10 D9 + school based education, 95%
coverage
1620 51.4 2192
D11 D10 + antiretroviral therapy, intensive
monitoring, first and second line drugs
2481 51.6 4406
*International dollars are a hypothetical unit of currency that has the same purchasing power
that the US$ has in the United States at a given point in time. Details of this approach are
discussed elsewhere.12
†Excludes combinations that were more costly but less effective than others (dominated
interventions) and those with higher incremental cost effectiveness ratios than more effective
options (weakly dominated interventions).
‡Intervention benefits are not comparable with current epidemiological estimates because
results in this analysis are computed in relation to a “no intervention” comparator, which
subtracts current levels of condom use, treatment of sexually transmitted infections, and
antiretroviral treatment.
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Conclusions
We emphasise that decisions are never made only on cost effec-
tiveness criteria. Many other factors influence priority setting.
For HIV/AIDS in particular, arguments have been made in sup-
port of general or specific intervention strategies based on ethi-
cal criteria and human rights, so policy makers should interpret
our results in the context of these other important considera-
tions.
A previous analysis indicated that the millennium develop-
ment goal for HIV/AIDS could be achieved by application of a
comprehensive response to prevention and treatment.7 Our
analysis suggests that the financial constraints to implementing
such a comprehensive approach to combating HIV/AIDS
should not be regarded as the principal obstacle. A critical policy
question that remains, however, is how to ensure that the massive
undertaking required to respond effectively to the HIV
pandemic can be sustained. Our findings that a combination of
prevention and treatment can be highly cost effective brings into
sharper focus the importance of overcoming other constraints
such as managerial needs, political commitment, infrastructure,
and human resource requirements.
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Amendment
This is Version 2 of the paper. In this version, minor changes
have been made to the text to clarify that the two regions
studied are based on WHO grouping according to overall
mortality, not HIV/AIDS epidemiology, and that cost
effectiveness was the sole criterion used in prioritising
interventions. A small correction in the discussion (p 5)
means it now states: “Cost effectiveness ratios for first line
HAART are lower than [not ‘similar to’] those for school
based education.”
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